- Home
- NUAI vs QNCX Comparison
NUAI vs QNCX Comparison
Compare NUAI & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUAI | QNCX |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.3M | 167.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NUAI | QNCX |
|---|---|---|
| Price | $4.14 | $0.09 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 3.1M | ★ 15.5M |
| Earning Date | 03-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.08 |
| 52 Week High | $9.45 | $4.55 |
Technical Indicators
Market Signals| Indicator | NUAI | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 39.29 | 28.62 |
| Support Level | $4.10 | N/A |
| Resistance Level | $5.16 | $0.98 |
| Average True Range (ATR) | 0.51 | 0.01 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 6.95 | 18.58 |
Price Performance
Historical ComparisonAbout NUAI New Era Energy & Digital Inc.
New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.